The global anti-microbial/anti-fungal tests market is set to achieve substantial growth, with industry experts projecting a market value of USD 2.5 billion by the end of 2022. This expansion is fueled by the increasing demand for effective microbial screening solutions and innovative antibiotics, showcasing a robust Compound Annual Growth Rate (CAGR) of 5.7%. Analysts anticipate the market will exceed USD 4.5 billion by 2032.
A recent comprehensive study has revealed that molecular-based tests are leading the market, accounting for approximately 53.5% of the share in 2021. This trend signifies a notable shift towards advanced testing methodologies that are crucial in combating microbial infections.
Microorganism screening has been foundational in research aimed at developing innovative antibiotics. Fungi and bacteria serve as prolific sources of antibiotics, with applications spanning agriculture, pharmaceuticals, and veterinary medicine. In these sectors, antimicrobials are essential for combatting bacterial growth and fungal infections.
Traditionally, antibiotics have been employed against bacteria but are also effective in antifungal applications. Moreover, bacteria themselves can be utilized to combat fungal infections. The significance of antimicrobial chemotherapeutics and prophylaxis cannot be overstated, as they provide vital tools for both treating and preventing infections.
In addition, antimicrobial susceptibility tests are pivotal for guiding physicians in selecting the most appropriate medication and dosage for complex infections, thereby optimizing patient outcomes.
As the global healthcare landscape continues to evolve, the importance of robust anti-microbial/anti-fungal testing methodologies becomes increasingly apparent. With the market poised for substantial growth in the coming years, stakeholders across various industries are encouraged to stay informed about emerging trends and innovations in microbial screening and antimicrobial development.
Key Takeaways: Anti-Microbial/Anti-fungal Tests Market:
- The US market leads the way due to a growing preference for doctor-recommended diagnostic tests before treatment. Patients are increasingly aware of medication side effects and want a proper diagnosis.
- Fueled by a rise in immunocompromised individuals and diseases like diabetes, China’s anti-microbial/anti-fungal test market is expected to see significant growth (7.1% CAGR). This is due to the increasing prevalence of invasive fungal infections (IFIs).
- Driven by a rising incidence of fungal infections, particularly Candida glabrata, and an aging population with chronic illnesses, Germany’s anti-microbial/anti-fungal tests market is poised for growth (7.1% CAGR).
Soaring Demand for Market Information: Uncover Detailed Trends and Insights in Our Report!
Key Companies Profiled:
- Abbott Laboratories
- bioMérieux SA
- Bio-Rad Laboratories Inc
- Bruker Corporation
- Danaher Corporation
- Erba Mannheim
- F. Hoffmann-La Roche AG
- Luminex Corporation
- Meridian Bioscience Inc
- Norgen Biotek Corp
- Omega Diagnostics Group Plc
- Qiagen N.V
- Quidel Corporation
- Thermo Fisher Scientific Inc
Key Market Segments Covered in Anti-microbial/Anti-fungal Tests Industry Research:
By Tests Type:
- Molecular Based Tests
- PCR Test
- DNA Microarray
- Phenotypic Resistance Tests
- Complex Test Panels
- Mass Spectrometry
- Rapid Diagnostic Tests
- E-Test Antibiotic/Antifungal Strips
- Biosensor Platforms
By Infection Type:
- Antimicrobial Resistance
- Methicillin-Resistant Staphylococcus Aureus
- Vancomycin-Resistant Enterococcus
- Multi-Drug-Resistant Mycobacterium tuberculosis
- Carbapenem-Resistant Enterobacteriaceae gut bacteria
- Microbial Infection
- Antifungal Resistance
- Candida infections
- Aspergillus infection
- Fusariosis
- Others
- Fungal Infection
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Clinics
- Community Health Centers
- Reference Laboratories
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube